Frazier Life Sciences invests globally in private and publicly-traded companies that discover, develop, and commercialize innovative biopharmaceuticals. Frazier Life Sciences manages over $3.9 billion in capital, including venture funds focusing on company creation and private companies, and a public fund focused on small and mid-cap public companies. Since 2005, over 60 Frazier Life Sciences portfolio companies, many of which were created or seeded by Frazier, have completed IPOs or M&As. The Frazier Life Sciences team consists of over 40 professionals with deep expertise in biopharmaceuticals, primarily located in
Palo Alto, California (headquarters), San Diego, Seattle, Boston, New York, and London.
For more information about Frazier Life Sciences, please visit www.frazierls.com.
Company Details
- Employees
- 40
- Industry
- Venture Capital And Private Equity Principals
- NAICS
-
Miscellaneous Intermediation
- Website
- https://www.frazierls.com
Frazier Life Sciences Questions
Frazier Life Sciences's website is https://www.frazierls.com
Frazier Life Sciences's LinkedIn profile is https://www.linkedin.com/company/frazier-life-sciences
Frazier Life Sciences has
40 employees.
View email and phone details for 40
employees at Frazier Life Sciences.
Frazier Life Sciences's industry is
Venture Capital and Private Equity Principals
Frazier Life Sciences's top competitors are
Hummingbird Bioscience,
Arch Venture Partners,
Callio Therapeutics,
Ra Capital Management,
Frazier Healthcare Partners,
Orbimed,
Nextech Invest,
5am Ventures,
Samsara Biocapital,
Hillstar Bio.
Frazier Life Sciences's categories are Venture Capital and Private Equity Principals
